What is neoX Biotech?
Founded in 2018, neoX Biotech operates at the intersection of high-performance computing and molecular biology. The company specializes in the application of AI-driven platforms to solve complex biophysical challenges, effectively streamlining the pipeline for drug research and development. By integrating deep learning with structural biology, neoX Biotech provides a robust framework for identifying drug candidates with higher efficacy and lower toxicity profiles. This technological edge allows the firm to address unmet medical needs, moving beyond traditional trial-and-error methodologies to a more predictive, data-centric approach to pharmaceutical innovation.
How much funding has neoX Biotech raised?
neoX Biotech has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2021): $30M with participation from 5Y Capital, Vertex Ventures, Sky9 Capital, and Bai Capital
Key Investors in neoX Biotech
5Y Capital
A prominent venture capital firm focused on early-to-growth stage investments in the technology and healthcare sectors, known for supporting disruptive innovation in China.
Vertex Ventures
Vertex Ventures US is an early-stage venture capital firm that supports founders creating a smarter digital economy through B2B software, leveraging a global network to provide operational insights.
Sky9 Capital
A venture capital firm specializing in early-stage investments across the technology, consumer, and enterprise sectors, with a strong focus on high-growth markets.
What's next for neoX Biotech?
Looking ahead, the recent capital influx will be directed toward scaling the company's AI infrastructure and expanding its internal R&D capabilities. As neoX Biotech transitions into a more mature phase of its lifecycle, the focus will likely shift toward clinical validation of its lead candidates and the formation of strategic partnerships with global pharmaceutical giants. The firm is well-positioned to capitalize on the growing demand for AI-enabled drug discovery, with the potential to disrupt conventional development timelines. Sustained growth will depend on the company's ability to maintain its technical lead while navigating the complex regulatory environments inherent in international drug development.
See full neoX Biotech company page
